{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T13:37:48Z","timestamp":1774791468794,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.msard.2022.104403","type":"journal-article","created":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T12:04:24Z","timestamp":1667909064000},"page":"104403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["High persistence and low adverse events burden in cladribine treated MS patients from Argentina"],"prefix":"10.1016","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9101-8203","authenticated-orcid":false,"given":"L.","family":"Negrotto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.C.","family":"Iut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Etchepare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"D'Eramo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Grinspan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Assefi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2022.104403_bib0001","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.msard.2018.11.021","article-title":"Safety of cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis","volume":"29","author":"Cook","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2022.104403_bib0002","article-title":"Multiple sclerosis epidemiology in Latin America: an updated survey","volume":"3","author":"Cristiano","year":"2017","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"629","key":"10.1016\/j.msard.2022.104403_bib0003","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3399\/bjgp14X682609","article-title":"What's new in multiple sclerosis?","volume":"64","author":"Dimitrov","year":"2014","journal-title":"Br. J. Gen. Pract."},{"issue":"1","key":"10.1016\/j.msard.2022.104403_bib0004","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","article-title":"Multiple sclerosis","volume":"4","author":"Filippi","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"3","key":"10.1016\/j.msard.2022.104403_bib0005","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1007\/s00415-021-10836-8","article-title":"Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis","volume":"269","author":"Filippi","year":"2022","journal-title":"J. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2022.104403_bib0006","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2022.104403_bib0007","doi-asserted-by":"crossref","unstructured":"Giovannoni, G., Soelberg Sorensen, P., Cook, S., Rammohan, K., Rieckmann, P., Comi, G., et\u00a0al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult. Scler. 24(12):1594\u20131604. doi: 10.1177\/1352458517727603.","DOI":"10.1177\/1352458517727603"},{"issue":"5","key":"10.1016\/j.msard.2022.104403_bib0008","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1007\/s00415-021-10956-1","article-title":"Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod-potentials and risks of subsequent highly active agents","volume":"269","author":"Korsen","year":"2022","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2022.104403_bib0009","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1474-4422(14)70005-5","article-title":"Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial","volume":"13","author":"Leist","year":"2014","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.msard.2022.104403_bib0010","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/1352458520921087","article-title":"Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: an MSBase registry substudy","volume":"27","author":"Lizak","year":"2021","journal-title":"Mult. Scler."},{"issue":"15 Suppl","key":"10.1016\/j.msard.2022.104403_bib0011","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1212\/WNL.94.15_supplement.1479","article-title":"Year 1 Performance of Adveva\u00ae, a Patient Support Program (PSP) for Patients Taking MAVENCLAD\u00ae (cladribine tablets) for Highly Active Relapsing Remitting Multiple Sclerosis (RRMS) in United Kingdom (UK)","volume":"94","author":"Morgan","year":"2020","journal-title":"Neurol"},{"key":"10.1016\/j.msard.2022.104403_bib0012","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.msard.2018.03.014","article-title":"Evolution of multiple sclerosis prevalence and phenotype in Latin America","volume":"22","author":"Negrotto","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104403_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102582","article-title":"Absence of latitudinal gradient in oligoclonal bands prevalence in Argentina","volume":"46","author":"Negrotto","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104403_bib0014","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420922685","article-title":"Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS)","volume":"13","author":"Patti","year":"2020","journal-title":"Ther Adv Neurol. Disord."},{"key":"10.1016\/j.msard.2022.104403_bib0015","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s40120-022-00364-6","article-title":"Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: a Real-World, Multicenter, 2-Year Follow-Up Study","volume":"11","author":"Petracca","year":"2022","journal-title":"Neurol Ther"},{"issue":"2","key":"10.1016\/j.msard.2022.104403_bib0016","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/13524585211012227","article-title":"Effectiveness and safety of cladribine in MS: real-world experience from two tertiary centres","volume":"28","author":"Pfeuffer","year":"2022","journal-title":"Mult. Scler."},{"issue":"18","key":"10.1016\/j.msard.2022.104403_bib0017","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1007\/s40265-020-01422-9","article-title":"The development of cladribine tablets for the treatment of multiple sclerosis: a comprehensive review","volume":"80","author":"Rammohan","year":"2020","journal-title":"DrugsDrugs"},{"issue":"2S","key":"10.1016\/j.msard.2022.104403_bib0018","first-page":"701","article-title":"Real world data from the argentine MS national registry of patients under cladribine","volume":"27","author":"Rojas","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104403_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.693017","article-title":"Early high efficacy treatment in multiple sclerosis is the best predictor of future disease activity over 1 and 2 years in a norwegian population-based registry","volume":"12","author":"Simonsen","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2022.104403_bib0020","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamaneurol.2021.2738","article-title":"Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: data From 2 Different National Strategies","volume":"78","author":"Spelman","year":"2021","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.msard.2022.104403_bib0021","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nrneurol.2016.188","article-title":"Treatment decisions in multiple sclerosis - insights from real-world observational studies","volume":"13","author":"Trojano","year":"2017","journal-title":"Nat. Rev. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822009075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822009075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:09:02Z","timestamp":1761901742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822009075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":21,"alternative-id":["S2211034822009075"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.104403","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High persistence and low adverse events burden in cladribine treated MS patients from Argentina","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.104403","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104403"}}